K D Lindor

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi request reprint Primary sclerosing cholangitis: diagnosis and management
    Phunchai Charatcharoenwitthaya
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, 200 First Street, SW, Rochester, MN 55905, USA
    Curr Gastroenterol Rep 8:75-82. 2006
  2. pmc Nonalcoholic fatty liver disease
    Leon A Adams
    Division of Gastroenterology and Hepatology, Mayo Clinic and College of Medicine, Rochester, Minn 55905, USA
    CMAJ 172:899-905. 2005
  3. ncbi request reprint The natural history of nonalcoholic fatty liver disease: a population-based cohort study
    Leon A Adams
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Gastroenterology 129:113-21. 2005
  4. ncbi request reprint Ursodeoxycholic acid for the treatment of primary biliary cirrhosis
    Keith Lindor
    Division of Gastroenterology and Hepatology, Fiterman Center for Digestive Disease, Mayo Clinic, Rochester, MN 55905, USA
    N Engl J Med 357:1524-9. 2007
  5. doi request reprint Treatment of primary biliary cirrhosis: therapy with choleretic and immunosuppressive agents
    Marina G Silveira
    Miles and Shirley Fiterman Center for Digestive Diseases, Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Clin Liver Dis 12:425-43; x-xi. 2008
  6. doi request reprint Farnesoid X receptor agonists for primary biliary cirrhosis
    Keith D Lindor
    Mayo Clinic, Rochester, Minnesota 55905, USA
    Curr Opin Gastroenterol 27:285-8. 2011
  7. pmc High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis
    Keith D Lindor
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA
    Hepatology 50:808-14. 2009
  8. ncbi request reprint Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial
    Keith D Lindor
    Division of Gastroenterology and Hepatology, Mayo Clinic W19A, 200 1st Street SW, Rochester, MN 55905, USA
    Hepatology 39:770-8. 2004
  9. doi request reprint New treatment strategies for primary sclerosing cholangitis
    Keith D Lindor
    Mayo Clinic, Rochester, MN 55905, USA
    Dig Dis 29:113-6. 2011
  10. ncbi request reprint Primary sclerosing cholangitis
    C O Zein
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA
    Semin Gastrointest Dis 12:103-12. 2001

Detail Information

Publications107 found, 100 shown here

  1. ncbi request reprint Primary sclerosing cholangitis: diagnosis and management
    Phunchai Charatcharoenwitthaya
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, 200 First Street, SW, Rochester, MN 55905, USA
    Curr Gastroenterol Rep 8:75-82. 2006
    ..Liver transplantation is a good option for patients with advanced PSC, although the disease can recur after successful transplantation...
  2. pmc Nonalcoholic fatty liver disease
    Leon A Adams
    Division of Gastroenterology and Hepatology, Mayo Clinic and College of Medicine, Rochester, Minn 55905, USA
    CMAJ 172:899-905. 2005
    ..In this article we discuss the etiology, pathogenesis and diagnosis of nonalcoholic fatty liver disease as well as approaches to its management...
  3. ncbi request reprint The natural history of nonalcoholic fatty liver disease: a population-based cohort study
    Leon A Adams
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Gastroenterology 129:113-21. 2005
    ..The natural history of nonalcoholic fatty liver disease (NAFLD) in the community remains unknown. We sought to determine survival and liver-related morbidity among community-based NAFLD patients...
  4. ncbi request reprint Ursodeoxycholic acid for the treatment of primary biliary cirrhosis
    Keith Lindor
    Division of Gastroenterology and Hepatology, Fiterman Center for Digestive Disease, Mayo Clinic, Rochester, MN 55905, USA
    N Engl J Med 357:1524-9. 2007
  5. doi request reprint Treatment of primary biliary cirrhosis: therapy with choleretic and immunosuppressive agents
    Marina G Silveira
    Miles and Shirley Fiterman Center for Digestive Diseases, Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Clin Liver Dis 12:425-43; x-xi. 2008
    ..Effective therapy reduces the need for transplantation and improves life expectancy. For advanced liver disease or incomplete response to UDCA, new therapies to cure or retard the progression of disease in PBC are needed...
  6. doi request reprint Farnesoid X receptor agonists for primary biliary cirrhosis
    Keith D Lindor
    Mayo Clinic, Rochester, Minnesota 55905, USA
    Curr Opin Gastroenterol 27:285-8. 2011
    ..This review will provide an overview of the role of nuclear receptors in bile acid homeostasis with a focus on the farnesoid X receptor (FXR) and its potential therapeutic use in cholestatic liver diseases...
  7. pmc High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis
    Keith D Lindor
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA
    Hepatology 50:808-14. 2009
    ..01]). Conclusion: Long-term, high-dose UDCA therapy is associated with improvement in serum liver tests in PSC but does not improve survival and was associated with higher rates of serious adverse events...
  8. ncbi request reprint Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial
    Keith D Lindor
    Division of Gastroenterology and Hepatology, Mayo Clinic W19A, 200 1st Street SW, Rochester, MN 55905, USA
    Hepatology 39:770-8. 2004
    ..In conclusion, 2 years of therapy with UDCA at a dose of 13 to 15 mg/kg/d, although safe and well tolerated, is not better than placebo for patients with NASH...
  9. doi request reprint New treatment strategies for primary sclerosing cholangitis
    Keith D Lindor
    Mayo Clinic, Rochester, MN 55905, USA
    Dig Dis 29:113-6. 2011
    ..Currently, there are multiple potential therapeutic avenues to explore for patients with PSC, and it is hoped that one of these will lead to identification of a proven therapy for this disease...
  10. ncbi request reprint Primary sclerosing cholangitis
    C O Zein
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA
    Semin Gastrointest Dis 12:103-12. 2001
    ..Although there is no known beneficial therapy for these patients, research aimed toward better understanding the pathogenetic mechanisms and clinical trials with promising new agents are ongoing...
  11. ncbi request reprint Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: a randomized placebo-controlled treatment trial
    A J Czaja
    Division of Gastroenterology and Hepatology, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Hepatology 30:1381-6. 1999
    ..Short-term therapy, however, does not facilitate reduction in the dose of corticosteroids or its withdrawal, affect clinical outcome, or reduce histological activity...
  12. ncbi request reprint Natural history of pruritus in primary biliary cirrhosis
    Jayant A Talwalkar
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Clin Gastroenterol Hepatol 1:297-302. 2003
    ..No significant risk reduction in developing pruritus with UDCA therapy was observed compared to placebo-treated patients. The long-term administration of rifampin for refractory pruritus is associated with occasional hepatotoxicity...
  13. ncbi request reprint Mycophenolate mofetil for the treatment of primary sclerosing cholangitis
    Jayant A Talwalkar
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, 200 SW First Street, Rochester, MN 55905, USA
    Am J Gastroenterol 100:308-12. 2005
    ..In conclusion, MMF does not appear to have clinically important benefits for PSC despite being tolerated by most patients. The results of this pilot study do not support further study of MMF as a single agent in the treatment of PSC...
  14. pmc Clinical features and management of primary sclerosing cholangitis
    Marina G Silveira
    Division of Gastroenterology and Hepatology, Miles and Shirley Fiterman Center for Digestive Diseases, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    World J Gastroenterol 14:3338-49. 2008
    ..A PSC-like variant attracting attention is cholangitis marked by raised levels of the immunoglobulin G4 subclass, prominence of plasma cells within the lesions, and steroid responsiveness...
  15. ncbi request reprint Development of autoimmune hepatitis in primary biliary cirrhosis
    Andrea A Gossard
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN, USA
    Liver Int 27:1086-90. 2007
    ..A subset, however, have no such features but go on to develop a 'sequential' AIH overlap syndrome. Objectives: Describe our experience with eight patients who developed AIH after the diagnosis of PBC was made...
  16. ncbi request reprint High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis
    D M Harnois
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 96:1558-62. 2001
    ..4). High-dose UDCA was well tolerated. CONCLUSIONS: UDCA at a dose of 25-30 mg/kg per day may be of benefit for patients with PSC, and this regimen deserves further evaluation in a long-term, randomized, placebo-controlled trial...
  17. doi request reprint Moexipril for treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid
    Phunchai Charatcharoenwitthaya
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Dig Dis Sci 55:476-83. 2010
    ..2) was associated with the treatment. Fatigue and health-related quality of life scores during treatment demonstrated a trend toward improvement. Moexipril was not clinically beneficial to PBC patients responding suboptimally to UDCA...
  18. ncbi request reprint Ursodeoxycholic acid inhibits eosinophil degranulation in patients with primary biliary cirrhosis
    K Yamazaki
    Department of Immunology, Mayo Clinic and Mayo Foundation, Rochester, MN, USA
    Hepatology 30:71-8. 1999
    ..Our results suggest that eosinophils in patients with PBC are not only increased in number, but also release granule proteins, and that UDCA treatment inhibits this eosinophil activation/degranulation...
  19. ncbi request reprint Primary sclerosing cholangitis: patients with a rising alkaline phosphatase at annual follow-up
    Phunchai Charatcharoenwitthaya
    Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Clin Gastroenterol Hepatol 5:32-6. 2007
  20. doi request reprint Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis - a pilot study
    J H Tabibian
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA
    Aliment Pharmacol Ther 37:604-12. 2013
    ..Emerging data suggest that oral antibiotics may have therapeutic effects in primary sclerosing cholangitis (PSC), but published studies are limited...
  21. doi request reprint Recurrent primary biliary cirrhosis after liver transplantation
    M G Silveira
    Miles and Shirley Fitterman Center for Digestive Diseases, Rochester, MN, USA
    Am J Transplant 10:720-6. 2010
    ..While short- and medium-term outcomes remain favorable, especially if compared to patients transplanted for other indications, continued follow-up may identify reduced long-term graft and patient survival...
  22. ncbi request reprint Epidemiology and natural history of primary biliary cirrhosis in a US community
    W R Kim
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Gastroenterology 119:1631-6. 2000
    ..We report the incidence and prevalence of this condition in the general population. We also examined the validity of the Mayo natural history model for PBC among these unselected patients from the community...
  23. ncbi request reprint Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis
    Flavia D Mendes
    Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 101:2070-5. 2006
    ..We sought to determine the frequency of elevated IgG4 in patients with PSC and to clinically compare PSC patients with elevated and normal IgG4 levels...
  24. pmc Primary sclerosing cholangitis
    Marina G Silveira
    Miles and Shirley Center for Digestive Dieseases, Mayo Clinic and Foundation for Medical Education and Research, Rochester, MN 55905, USA
    Can J Gastroenterol 22:689-98. 2008
    ....
  25. ncbi request reprint The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies
    Leon A Adams
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    J Hepatol 42:132-8. 2005
    ..The histological course of nonalcoholic fatty liver disease (NAFLD) remains undescribed. Therefore, we examined the liver histology of NAFLD patients who had undergone sequential liver biopsies...
  26. doi request reprint Current therapies for nonalcoholic fatty liver disease
    A A Gossard
    Mayo Clinic, Rochester, Minnesota 55901, USA
    Drugs Today (Barc) 47:915-22. 2011
    ..In this paper, we review the literature pertaining to the current state of NAFLD management with an emphasis on pharmacotherapy...
  27. ncbi request reprint Incomplete response to ursodeoxycholic acid in primary biliary cirrhosis: is a double dosage worthwhile?
    P Angulo
    Division of Gastroenterology and Hepatology, Mayo Clinic Foundation, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 96:3152-7. 2001
    ....
  28. ncbi request reprint Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study
    M F Abdelmalek
    Divisions of Gastroenterology and Hepatology and Surgical Pathology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 96:2711-7. 2001
    ..CONCLUSIONS: Betaine is a safe and well tolerated drug that leads to a significant biochemical and histological improvement in patients with NASH. This novel agent deserves further evaluation in a randomized, placebo-controlled trial...
  29. ncbi request reprint Treatment of cholangiocarcinoma complicating primary sclerosing cholangitis: the Mayo Clinic experience
    M Kaya
    Division of Gastroenterology and Hepatology, Mayo Clinic and General Foundation, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 96:1164-9. 2001
    ..However, these therapies are rarely applied to these patients because of the advanced nature of the disease at the time of diagnosis. Efforts should be directed at earlier identification of potential surgical candidates...
  30. ncbi request reprint Reliability and validity of the NIDDK-QA instrument in the assessment of quality of life in ambulatory patients with cholestatic liver disease
    W R Kim
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN, USA
    Hepatology 32:924-9. 2000
    ..These data, combined with our previous study, demonstrate its applicability in a wide spectrum of disease severity, ranging from early, ambulatory-phase disease to decompensated cirrhosis necessitating liver transplantation...
  31. ncbi request reprint Mycophenolate mofetil for the treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid
    Jayant A Talwalkar
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    J Clin Gastroenterol 39:168-71. 2005
    ..Mycophenolate mofetil (MMF) is an immunosuppressive medication that inhibits T and B lymphocyte proliferation. The aim of this investigation was to determine the safety and estimated efficacy of MMF in patients with PBC...
  32. ncbi request reprint The prevalence of autoantibodies and autoimmune hepatitis in patients with nonalcoholic Fatty liver disease
    Leon A Adams
    Division of Gastroenterology and Hepatology, Mayo Medical School, Clinic and Foundation, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 99:1316-20. 2004
    ..We aimed at examining the prevalence of autoantibodies and autoimmune hepatitis among patients with NAFLD...
  33. ncbi request reprint Cost-minimization analysis of MRC versus ERCP for the diagnosis of primary sclerosing cholangitis
    Jayant A Talwalkar
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Hepatology 40:39-45. 2004
    ..30 US dollars would be required. In conclusion, MRC has comparable accuracy to ERCP and results in cost savings when used as the initial test strategy for diagnosing PSC...
  34. ncbi request reprint Fluoxetine for the treatment of fatigue in primary biliary cirrhosis: a randomized, double-blind controlled trial
    Jayant A Talwalkar
    Division of Gastroneterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Dig Dis Sci 51:1985-91. 2006
    ..Three of the four patients had drug-related adverse events with fluoxetine. In this study, fluoxetine did not improve fatigue in PBC and was associated with adverse events...
  35. ncbi request reprint Silymarin in the treatment of patients with primary sclerosing cholangitis: an open-label pilot study
    Paul Angulo
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Dig Dis Sci 53:1716-20. 2008
    ..The results of this pilot study warrant further evaluation of silymarin in patients with PSC in a large-scale, controlled trial...
  36. ncbi request reprint Recent advances in the treatment of non-alcoholic fatty liver disease
    Flavia D Mendes
    Mayo Clinic College of Medicine, Gastroenterology and Hepatology, 200 First Street, SW Rochester, MN, USA
    Expert Opin Investig Drugs 14:29-35. 2005
    ..Despite promising results, no therapy has demonstrated a proven benefit...
  37. ncbi request reprint Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease
    Paul Angulo
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55095, USA
    J Hepatol 41:943-9. 2004
    ..We aimed at determining the relation between leptin and liver fibrosis in human NAFLD...
  38. ncbi request reprint Primary sclerosing cholangitis
    Jayant A Talwalkar
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN, USA
    Inflamm Bowel Dis 11:62-72. 2005
    ..Liver transplantation remains the only successful treatment option for patients with advanced liver disease from PSC. A diagnosis of PSC should be considered among individuals with IBD and elevated serum liver biochemical tests...
  39. ncbi request reprint Living donor liver transplantation using a right lobe graft in an adult with situs inversus
    Julie K Heimbach
    Division of Transplantation Surgery, Mayo Clinic, 200 First Street, Rochester, MN 55905, USA
    Liver Transpl 11:111-3. 2005
    ..This is the first report of a successful living donor right liver graft in an adult with end-stage liver disease secondary to primary sclerosing cholangitis and situs inversus totalis...
  40. ncbi request reprint Open-label pilot study of folic acid in patients with nonalcoholic steatohepatitis
    Phunchai Charatcharoenwitthaya
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Liver Int 27:220-6. 2007
    ....
  41. ncbi request reprint When is liver biopsy needed in the diagnosis of primary biliary cirrhosis?
    Claudia O Zein
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Clin Gastroenterol Hepatol 1:89-95. 2003
    ..This study was undertaken to determine which variables indicate the need for liver biopsy in patients with positive AMA and suspected PBC...
  42. doi request reprint Pharmacological treatment of biliary cirrhosis with ursodeoxycholic acid
    Ghulam Abbas
    Mayo Clinic, Division of Gastroenterology and Hepatology, 20 First Street SW, Rochester, MN 55905, USA
    Expert Opin Pharmacother 11:387-92. 2010
    ..Primary biliary cirrhosis is a cholestatic liver disease that at one time was the leading indication for liver transplantation. Treatment with ursodeoxycholic acid has clearly improved the natural history of primary biliary cirrhosis...
  43. doi request reprint Latest and emerging therapies for primary biliary cirrhosis and primary sclerosing cholangitis
    Claudia O Zein
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Curr Gastroenterol Rep 12:13-22. 2010
    ..In PBC and PSC, adequate management of complications of chronic cholestasis is important. For both diseases, liver transplantation is the only curative option...
  44. doi request reprint Nonalcoholic fatty liver disease and the coronary artery disease
    Sombat Treeprasertsuk
    Division of Gastroenterology and Hepatology, Mayo Clinic, Fiterman Center for Digestive Diseases, 200 First Street, SW, Rochester, MN 55905, USA
    Dig Dis Sci 56:35-45. 2011
    ..Patients with NAFLD have a lower life expectancy compared to the general population, with coronary artery disease (CAD) as the leading cause of death...
  45. ncbi request reprint Putting the needs of the patient first: Mayo Clinic's core value, institutional culture, and professionalism covenant
    Thomas R Viggiano
    Mayo Medical School, Mayo Clinic, Rochester, Minnesota 55905, USA
    Acad Med 82:1089-93. 2007
    ....
  46. doi request reprint Gender differences in academic productivity and leadership appointments of physicians throughout academic careers
    Darcy A Reed
    Division of Primary Care, Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Acad Med 86:43-7. 2011
    ..The authors aimed to compare the publication records, academic promotions, and leadership appointments of women and men physicians longitudinally throughout academic careers...
  47. doi request reprint Overlap syndromes with autoimmune hepatitis in chronic cholestatic liver diseases
    Marina G Silveira
    Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Expert Rev Gastroenterol Hepatol 1:329-40. 2007
    ..Further studies are needed for determining diagnosis, natural history and optimal therapeutic strategies of overlap syndromes of autoimmune liver disease...
  48. ncbi request reprint Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis
    Darrell S Pardi
    Division of Gastroenterology and Hepatology and Division of Biostatistics, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Gastroenterology 124:889-93. 2003
    ..We sought to evaluate the effect of UDCA on colorectal neoplasia in a group of patients with UC and PSC enrolled in a randomized, placebo-controlled trial...
  49. ncbi request reprint Increased prevalence of antimitochondrial antibodies in first-degree relatives of patients with primary biliary cirrhosis
    Konstantinos N Lazaridis
    Center for Basic Research in Digestive Diseases, Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Hepatology 46:785-92. 2007
    ..1% and 1%, respectively. Greater prevalence of AMA was found in female FDRs of PBC probands [sisters (20.7%), mothers (15.1%), and daughters (9.8%)] than in male FDRs [brothers (7.8%), fathers (3.7%), and sons (0%)]...
  50. ncbi request reprint Primary sclerosing cholangitis in children: a long-term follow-up study
    Ariel E Feldstein
    Division of Gastroenterology and Hepatology, Department of Pediatric and Adolescent Medicine, Mayo Medical School, Clinic and Foundation, Rochester, MN 55905, USA
    Hepatology 38:210-7. 2003
    ..In conclusion, PSC significantly decreases survival in this child population. Although pharmacologic therapy may improve symptoms and liver test results initially, it does not seem to impact the long-term outcome...
  51. ncbi request reprint Management of osteoporosis, fat-soluble vitamin deficiencies, and hyperlipidemia in primary biliary cirrhosis
    Cynthia Levy
    Gastroenterology and Hepatology, Mayo Clinic Rochester, 200 1st Street, SW E 19 B, Rochester, MN 55905, USA
    Clin Liver Dis 7:901-10. 2003
    ..Finally, hyperlipidemia in PBC does not seem to be associated with an increased risk of atherogenesis. New therapies in this patient population are currently under investigation...
  52. pmc High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis
    M H Imam
    Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Aliment Pharmacol Ther 34:1185-92. 2011
    ..Ursodeoxycholic acid (UDCA) in a dose of 28-30 mg/kg/day increases the likelihood of clinical deterioration of primary sclerosing cholangitis (PSC) patients...
  53. ncbi request reprint Severe cholestatic hepatitis from troglitazone in a patient with nonalcoholic steatohepatitis and diabetes mellitus
    P Angulo
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 96:1631-4. 2001
    ..Further data are needed before more widespread use of troglitazone can be recommended for patients with nonalcoholic steatohepatitis...
  54. ncbi request reprint Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis
    A J Czaja
    Division of Gastroenterology and Hepatology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Gastroenterology 119:1312-6. 2000
    ..Our goals were to assess budesonide in patients with treatment-dependent autoimmune hepatitis and to determine if efficacy and safety justified a controlled trial...
  55. ncbi request reprint Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation
    Phunchai Charatcharoenwitthaya
    Miles and Shirley Fitterman Center for Digestive Diseases, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Liver Transpl 13:1236-45. 2007
    ..In this short period of treatment, UDCA was not associated with improved patient and graft survival compared to untreated patients...
  56. ncbi request reprint Overlap of autoimmune hepatitis and primary biliary cirrhosis: long-term outcomes
    Marina G Silveira
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 102:1244-50. 2007
    ..Patients with PBC should receive ursodeoxycholic acid (UDCA); the role of and response to additional immunosuppressive therapy are unknown when AIH overlaps PBC...
  57. ncbi request reprint Secondary sclerosing cholangitis: a comparison to primary sclerosing cholangitis
    Andrea A Gossard
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 100:1330-3. 2005
    ..We also compared the natural history of patients diagnosed with SSC to a cohort with a diagnosis of primary sclerosing cholangitis (PSC)...
  58. ncbi request reprint Fatigue in primary biliary cirrhosis
    Ghulam Abbas
    Division of Gastroenterology and Hepatology, Mayo Clinic, 20 First Street, SW Rochester, MN 55905, USA
    Nat Rev Gastroenterol Hepatol 7:313-9. 2010
    ..The central and the peripheral mechanisms that have been suggested for the pathogenesis of fatigue in PBC are also discussed and treatment options are reviewed...
  59. doi request reprint Thyroid dysfunction in primary biliary cirrhosis, primary sclerosing cholangitis and non-alcoholic fatty liver disease
    Marina G Silveira
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA
    Liver Int 29:1094-100. 2009
    ..Primary biliary cirrhosis (PBC) is frequently associated with autoimmune diseases, including thyroid disease, although it is uncertain that this association is higher than in other liver diseases...
  60. ncbi request reprint Primary biliary cirrhosis: an infectious disease caused by Chlamydia pneumoniae?
    Ahmad S Abdulkarim
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    J Hepatol 40:380-4. 2004
    ..Both an infectious etiology and molecular mimicry have been implicated. The aim is to study the prevalence of Chlamydial antigens and RNA in the liver tissue of patients with PBC...
  61. ncbi request reprint A pilot trial of pentoxifylline in nonalcoholic steatohepatitis
    Leon A Adams
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 99:2365-8. 2004
    ..Pentoxifylline inhibits TNF alpha production. We therefore conducted a 12-month pilot trial to assess the efficacy and safety of pentoxifylline (1,600 mg/day) among 20 patients with NASH...
  62. ncbi request reprint Is there a role for liver biopsy in primary sclerosing cholangitis?
    Kelly W Burak
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 98:1155-8. 2003
    ..The purpose of this study was to examine how often routine liver biopsies provide important information in patients with PSC...
  63. ncbi request reprint Results of long-term ursodiol treatment for patients with primary biliary cirrhosis
    Roberta Jorgensen
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 97:2647-50. 2002
    ..To address this, we reviewed the long-term results from patients enrolled in our original randomized study with up to 12 yr of follow-up...
  64. doi request reprint Complications of endoscopic retrograde cholangiopancreatography in primary sclerosing cholangitis
    Sanjay Y Bangarulingam
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 104:855-60. 2009
    ..The risk of complications associated with this procedure is not well established in these patients. The aim of this retrospective study was to compare the risk of ERCP complications in PSC vs. non-PSC patients...
  65. ncbi request reprint Impact of inflammatory bowel disease and ursodeoxycholic acid therapy on small-duct primary sclerosing cholangitis
    Phunchai Charatcharoenwitthaya
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Hepatology 47:133-42. 2008
    ..001) in UDCA-treated patients, while no significant change occurred in untreated patients. UDCA therapy had no effect on delaying progression of disease (relative risk, 0.95; 95% confidence interval, 0.38-2.36)...
  66. ncbi request reprint Raloxifene improves bone mass in osteopenic women with primary biliary cirrhosis: results of a pilot study
    Cynthia Levy
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA
    Liver Int 25:117-21. 2005
    ..Bone disease is common in patients with primary biliary cirrhosis (PBC). Our aim was to evaluate safety and efficacy of raloxifene in this population...
  67. doi request reprint Colonic neoplasia in young patients with inflammatory bowel disease and primary sclerosing cholangitis
    M H Imam
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Colorectal Dis 15:198-203. 2013
    ..The aim of our study was to validate the need for annual surveillance for colon neoplasia in patients ≤45 of age with a combined diagnosis of PSC and IBD...
  68. ncbi request reprint An update on primary sclerosing cholangitis:from pathogenesis to treatment
    M H Imam
    Division of Gastroenterology and Hepatology Mayo Clinic, Cholestatic Liver Diseases Study Group, Rochester, MN, USA
    Minerva Gastroenterol Dietol 59:49-58. 2013
    ..In this review we highlight recent advances in PSC pathogenesis, diagnosis and management...
  69. ncbi request reprint Development of autoimmune hepatitis in the setting of long-standing primary biliary cirrhosis
    P Angulo
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 96:3021-7. 2001
    ..The importance of its recognition and the appropriate management modifications are discussed...
  70. ncbi request reprint Dysphagia without endoscopically evident disease: to dilate or not?
    J S Scolapio
    Division of Gastroenterology and Hepatology, Mayo Clinic Jacksonville, Florida, USA
    Am J Gastroenterol 96:327-30. 2001
    ..The aim of this prospective study was to determine whether patients with solid food dysphagia and normal upper endoscopy have symptomatic benefit from empiric dilation using a through-the-scope balloon...
  71. ncbi request reprint Treatment of nonalcoholic fatty liver: present and emerging therapies
    P Angulo
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Semin Liver Dis 21:81-8. 2001
    ....
  72. ncbi request reprint Balloon dilation compared to stenting of dominant strictures in primary sclerosing cholangitis
    M Kaya
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 96:1059-66. 2001
    ..Stenting was associated with more complications, and its role after dilation should be assessed in a randomized trial rather than being accepted as routinely indicated in this setting...
  73. ncbi request reprint Bone disease in primary biliary cirrhosis: independent indicators and rate of progression
    K V Menon
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN, USA
    J Hepatol 35:316-23. 2001
    ..PBC patients who are older, thinner and have more advanced liver disease may have the most benefit from bone density measurements and treatment for their osteoporosis...
  74. ncbi request reprint Fat-soluble vitamin levels in patients with primary biliary cirrhosis
    J R Phillips
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 96:2745-50. 2001
    ..0. CONCLUSION: Other than deficiency of vitamin A, deficiency of fat-soluble vitamins occurs uncommonly in patients with PBC. A Mayo risk score > or = 5 helps in selecting patients with PBC for surveillance for vitamin A deficiency...
  75. doi request reprint Review article: nuclear receptors and liver disease--current understanding and new therapeutic implications
    D A H Elfaki
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55901, USA
    Aliment Pharmacol Ther 30:816-25. 2009
    ..These findings led to the introduction of targeting nuclear receptors as treatment strategies for various liver diseases...
  76. doi request reprint Minocycline in the treatment of patients with primary sclerosing cholangitis: results of a pilot study
    Marina G Silveira
    Division of Gastroenterology and Hepatology, Miles and Shirley Fiterman Center for Digestive Diseases, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Am J Gastroenterol 104:83-8. 2009
    ..Minocycline may also inhibit cell death pathways by reducing both proapoptotic and proinflammatory enzyme activation. We sought to investigate the safety and efficacy of minocycline among patients with PSC...
  77. ncbi request reprint Overlap of autoimmune hepatitis and primary biliary cirrhosis: an evaluation of a modified scoring system
    Jayant A Talwalkar
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 97:1191-7. 2002
    ..Our specific aim was to evaluate the revised IAHG scoring system and its ability to identify AIH overlap in PBC...
  78. ncbi request reprint Pregnancy in a patient with primary sclerosing cholangitis
    Andrea A Gossard
    Divison of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, Minnesota, USA
    J Clin Gastroenterol 35:353-5. 2002
    ..A healthy baby boy was delivered at 33.5 weeks. The mother required cholangiography and stent placement immediately after delivery, but her postpartum course was otherwise unremarkable...
  79. ncbi request reprint Non-alcoholic fatty liver disease
    Paul Angulo
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, Minnesota, USA
    J Gastroenterol Hepatol 17:S186-90. 2002
    ..Liver transplantation is a life-extending therapeutic alternative for patients with end-stage NAFLD, but NAFLD may recur after liver transplantation...
  80. ncbi request reprint Pirfenidone in the treatment of primary sclerosing cholangitis
    Paul Angulo
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, Minnesota P 55905, USA
    Dig Dis Sci 47:157-61. 2002
    ..Pirfenidone did not benefit patients with PSC, and it was frequently associated with adverse events. The results of this pilot study discourage further trials of pirfenidone in patients with PSC...
  81. pmc The predictors of the presence of varices in patients with primary sclerosing cholangitis
    Sombat Treeprasertsuk
    Division of Gastroenterology and Hepatology, Mayo Clinic Rochester, Rochester, MN, USA
    Hepatology 51:1302-10. 2010
    ..Lower platelet count and higher total bilirubin at 2 years were significantly associated with an increased risk of developing new varices in patients with PSC...
  82. ncbi request reprint Prevalence and predictors of esophageal varices in patients with primary sclerosing cholangitis
    Claudia O Zein
    Division of Gastroenterology and Hepatology, Mayo Medical School, Clinic and Foundation, Rochester, MN, USA
    Hepatology 39:204-10. 2004
    ..Our results suggest a clinically applicable and useful approach to identify patients with PSC who are more likely to benefit from endoscopic screening for esophageal varices...
  83. ncbi request reprint Treatment with ursodeoxycholic acid is associated with weight gain in patients with primary biliary cirrhosis
    Joanna L Siegel
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation Rochester, Minnesota 55905, USA
    J Clin Gastroenterol 37:183-5. 2003
    ..Ursodeoxycholic acid (UDCA) is the established treatment of primary biliary cirrhosis (PBC) and is a safe and well-tolerated medication. Nevertheless, patients often anecdotally complain of weight gain while on this drug...
  84. ncbi request reprint Nutritional and metabolic considerations in the etiology of nonalcoholic steatohepatitis
    V Nehra
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Dig Dis Sci 46:2347-52. 2001
    ..Neither choline deficiency nor celiac sprue by anti-endomysial antibody testing was associated with NASH...
  85. ncbi request reprint Natural history and prognostic models in primary sclerosing cholangitis
    J A Talwalkar
    Division of Gastroenterology and Hepatology, Mayo Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Best Pract Res Clin Gastroenterol 15:563-75. 2001
    ..Additionally, these models have also been employed for determining the optimal selection and timing for liver transplantation when advanced disease is imminent...
  86. ncbi request reprint Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'
    K N Lazaridis
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, 55905, USA
    J Hepatol 35:134-46. 2001
    ....
  87. doi request reprint Utility of liver biopsy in bone marrow transplant patients
    Prabhleen Chahal
    Division of Gastroenterology and Hepatology, University of Florida, Gainesville, FL, USA
    J Gastroenterol Hepatol 23:222-5. 2008
    ..During the complex clinical management of these patients, liver biopsies may be obtained during evaluation of abnormal liver tests. The purpose of our study was to assess the safety and use of liver biopsy in this patient population...
  88. ncbi request reprint Small-duct primary sclerosing cholangitis: a long-term follow-up study
    Paul Angulo
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Hepatology 35:1494-500. 2002
    ..Some patients, however, progress to classic PSC and/or end-stage liver disease with the consequent necessity of liver transplantation...
  89. doi request reprint Cholangiocarcinoma: expanding the spectrum of risk factors
    Diaa H Elfaki
    Division of Gastroenterology and Hepatology, Mayo Clinic, W19A, 200 First Street, SW, Rochester, MN 55905, USA
    J Gastrointest Cancer 39:114-7. 2008
    ..We also report two cases in which CCA developed in patients without previously determined risk factors known for CCA...
  90. doi request reprint Surveillance for hepatocellular carcinoma in patients with primary biliary cirrhosis
    Marina G Silveira
    Miles and Shirley Fiterman Center for Digestive Diseases, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA
    Hepatology 48:1149-56. 2008
    ..All cases of HCC except one were predicted to be at significant risk for HCC based on age, sex, evidence of portal hypertension, and history of blood transfusion using a previous predictive model...
  91. ncbi request reprint Primary biliary cirrhosis
    Jayant A Talwalkar
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Lancet 362:53-61. 2003
    ..Despite advances in understanding of the disease, it remains one of the major indications for liver transplantation worldwide...
  92. doi request reprint Long-term outcomes of positive fluorescence in situ hybridization tests in primary sclerosing cholangitis
    Sanjay Y Bangarulingam
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA
    Hepatology 51:174-80. 2010
    ..The FISH polysomy patients without cancer compared with those with CCA had lower serum bilirubin, lower carbohydrate antigen 19-9 (CA 19-9), lower Mayo risk score, and lower occurrence of dominant strictures...
  93. pmc Quality of life and everyday activities in patients with primary biliary cirrhosis
    Carlo Selmi
    Division of Rheumatology, Allergy, and Clinical Immunology, University of California, Davis, CA 95616, USA
    Hepatology 46:1836-43. 2007
    ..Nevertheless, patients with PBC suffer significantly more than controls from a variety of symptoms that are beyond the immediate impact of liver failure and affect their lifestyle, personal relationships, and work activities...
  94. ncbi request reprint Recurrence of primary sclerosing cholangitis: what do we learn from several transplant centers?
    Phunchai Charatcharoenwitthaya
    Liver Transpl 14:130-2. 2008
  95. ncbi request reprint Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis
    Renee Eugenie Poupon
    Inserm Unit 370, Faculte de Medecine Necker, 156 rue de Vaugirard, 75730 Paris Cedex 15, France
    J Hepatol 39:12-6. 2003
    ..This study aimed at evaluating the effect of ursodeoxycholic acid (UDCA) treatment on histologic progression in primary biliary cirrhosis (PBC)...
  96. ncbi request reprint Methotrexate therapy for primary biliary cirrhosis
    Nancy Bach
    Department of Medicine, Mount Sinai School of Medicine, New York, New York 10029, USA
    Am J Gastroenterol 98:187-93. 2003
    ..Preliminary data suggested possible benefits of methotrexate in primary biliary cirrhosis. We assessed the effectiveness of methotrexate use in primary biliary cirrhosis and its tolerance in patients with this disease...
  97. ncbi request reprint Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid
    Supriya Joshi
    Department of Medicine, The University Health Network, University of Toronto, Toronto, Ontario, Canada
    Hepatology 35:409-13. 2002
    ..Survival was similar for patients with PBC with and without ANA. In conclusion, features of AIH in PBC may be transient and response to UDCA therapy similar to patients with PBC without features of AIH...
  98. ncbi request reprint Human leukocyte antigen Class II associations in serum antimitochondrial antibodies (AMA)-positive and AMA-negative primary biliary cirrhosis
    Julianne Stone
    Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, BC, Canada
    J Hepatol 36:8-13. 2002
    ..We compared the frequency of HLA Class II genes in AMA-positive and AMA-negative PBC patients and healthy controls...
  99. ncbi request reprint A novel incentive system for faculty in an academic medical center
    Terry L Brandt
    Administrative Services, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Ann Intern Med 137:738-43. 2002
    ..This system led to increased faculty productivity, improved patient access, enhanced scholarly activity, and overall enhanced career satisfaction...
  100. doi request reprint Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis
    Phunchai Charatcharoenwitthaya
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Hepatology 48:1106-17. 2008
    ....
  101. doi request reprint High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis
    Marina G Silveira
    J Hepatol 48:692-4. 2008

Research Grants10